Physician profile
Binalkumar Ladani
NPI 1770700668
$674.16
in general payments reported to CMS, 2019-2025
10 companies · $18.22 in 2025
The $18.22 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $15.30 · 2021: $57.80 · 2022: $37.47 · 2023: $133 · 2024: $305 · 2025: $18.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $231.34 | 2023-2024 | Givlaari |
| Boston Scientific Corporation | $136.14 | 2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.49 | 2019-2025 | Lifevest |
| Pfizer INC. | $69.80 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $41.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.88 | 2022 | |
| Gilead Sciences, INC. | $18.59 | 2022 | |
| Glaxosmithkline, LLC. | $16.22 | 2021 | |
| Merck Sharp & Dohme LLC | $15.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binalkumar Ladani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.